AyushNet
Butea monosperma (Palasha) in androgenetic alopecia: a phytotherapeutic approach
Article

Butea monosperma (Palasha) in androgenetic alopecia: a phytotherapeutic approach

Introduction

Androgenetic alopecia (AGA) is a progressive, non-scarring hair loss disorder characterized by follicular miniaturization, shortened anagen phase, and gradual conversion of terminal hairs into vellus-like hairs. It is mediated primarily by genetic predisposition and androgen signaling, particularly the activity of dihydrotestosterone (DHT) acting on androgen-sensitive hair follicles in the frontal and vertex scalp.

Current standard therapies include 5α-reductase inhibitors (finasteride, dutasteride) and topical minoxidil; however, limitations such as adverse effects, variable response, and need for long-term adherence have encouraged exploration of phytotherapeutic alternatives. In this context, Butea monosperma (Palasha), a medicinal plant widely used in traditional systems of medicine, is being investigated for its potential role in hair follicle modulation and androgen-related alopecia.

Phytochemical profile of Butea monosperma relevant to hair biology

Butea monosperma contains a wide spectrum of bioactive constituents, including flavonoids (butrin, isobutrin), chalcones, triterpenoids, tannins, sterols, and glycosides. These compounds exhibit antioxidant, anti-inflammatory, antimicrobial, and endocrine-modulating properties that may be relevant in the pathophysiology of androgenetic alopecia.

Key phytochemical actions include:

  • Flavonoids: antioxidant and anti-inflammatory effects
  • Chalcones: modulation of cellular signaling pathways
  • Tannins: astringent and follicular conditioning properties
  • Sterols: potential influence on androgen metabolism pathways

Pathophysiology of androgenetic alopecia and therapeutic targets

AGA involves multiple interlinked mechanisms:

  • Androgen-dependent miniaturization of hair follicles
  • Conversion of testosterone to DHT via 5α-reductase enzyme
  • Shortening of anagen phase and prolongation of telogen phase
  • Perifollicular microinflammation
  • Oxidative stress–mediated follicular damage
  • Stem cell dysfunction in hair follicle bulge region

Therapeutic strategies therefore focus on:

  • Inhibition of 5α-reductase activity
  • Reduction of follicular inflammation
  • Improvement of scalp microcirculation
  • Antioxidant protection of dermal papilla cells
  • Promotion of anagen phase re-entry

Mechanistic basis of Butea monosperma in androgenetic alopecia

Potential 5α-reductase modulatory activity:

Preclinical phytochemical analyses suggest that plant-derived flavonoids and sterols may influence androgen metabolism pathways, including partial inhibition of 5α-reductase activity. This could theoretically reduce DHT-mediated follicular miniaturization.

Anti-inflammatory effects on follicular microenvironment:

Chronic perifollicular inflammation contributes to progressive hair follicle damage in AGA. Butea monosperma exhibits anti-inflammatory properties via suppression of pro-inflammatory mediators such as cytokines and eicosanoids, potentially improving follicular survival.

Antioxidant protection of hair follicle cells:

Oxidative stress plays a key role in dermal papilla cell apoptosis and follicular aging. The flavonoid-rich fraction of Butea monosperma scavenges reactive oxygen species and may protect hair follicle stem cells from oxidative injury.

Improvement of scalp microenvironment:

Tannins and phytosterols may contribute to improved scalp conditioning, reduced microbial imbalance, and enhanced follicular anchorage through astringent and barrier-stabilizing effects.

Support of hair cycle regulation:

By modulating inflammatory and oxidative pathways, Butea monosperma may indirectly support prolongation of the anagen phase and delay follicular transition to catagen/telogen phases.

Experimental and evidence landscape

Although direct large-scale clinical trials on Butea monosperma in androgenetic alopecia are limited, related pharmacological studies on its extracts demonstrate antioxidant, anti-inflammatory, and cytoprotective properties relevant to hair follicle biology. These findings support its potential as a candidate phytotherapeutic agent in early-stage AGA and adjunctive hair care formulations.

Therapeutic role in androgenetic alopecia

Butea monosperma may contribute to AGA management through:

  • Modulation of androgen-related pathways (potential 5α-reductase influence)
  • Reduction of perifollicular inflammation
  • Protection of dermal papilla cells from oxidative damage
  • Support of hair follicle cycling and anagen maintenance
  • Improvement of scalp health and follicular environment

Advantages of Butea monosperma–based phytotherapy

  • Multitarget action addressing hormonal, inflammatory, and oxidative components
  • Natural antioxidant and cytoprotective profile
  • Potential role as adjunct to standard AGA therapies
  • Lower risk of systemic hormonal side effects compared to synthetic anti-androgens
  • Compatibility with topical and cosmeceutical formulations1
  • Ethnomedicinal background supporting traditional use in skin and hair disorders

Limitations and research gaps

  • Lack of robust randomized controlled clinical trials in AGA
  • Insufficient standardized extraction and dosing protocols
  • Limited mechanistic studies specifically on hair follicle signaling pathways
  • Need for formulation optimization for scalp penetration and bioavailability
  • Variability in phytochemical composition depending on plant source

Conclusion

Butea monosperma (Palasha) represents a promising phytotherapeutic candidate in androgenetic alopecia due to its antioxidant, anti-inflammatory, and potential androgen-modulating properties. Its multitarget biological actions align with key pathogenic mechanisms of follicular miniaturization and hair cycle disruption. However, current evidence remains largely preclinical, and well-designed clinical studies are required to validate its efficacy, safety, and therapeutic positioning in evidence-based trichology.

References:

  1. Dubey A, Upadhyay RK. Phytochemistry, pharmacological potential, and therapeutic uses of (Palash) Butea monosperma: A review. International Journal of Green Pharmacy. Jan-Mar 2026 • 20 (1). https://www.researchgate.net/profile/Ravi-Upadhyay/publication/405180515_Phytochemistry_pharmacological_potential_and_therapeutic_uses_of_Palash_Butea_monosperma_A_review/links/6a11077c8318ce33b324a97c/Phytochemistry-pharmacological-potential-and-therapeutic-uses-of-Palash-Butea-monosperma-A-review.pdf